MRNA Sep 2024 75.000 put
- Benzinga
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
On Friday, the FDA approved Moderna Inc’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna, the first being the famed COVID-19 vaccine. Earlier this month, the FDA, citing administrative constraints, delayed the review of the vaccine’s applicat
- AFP
US approves Moderna's RSV vaccine for older adults
The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults -- marking the first time any mRNA shot has been authorized against a disease other than Covid-19.A global study of approximately 37,000 people aged 60 and older found the shot had an efficacy of 83.7 percent against lower respiratory tract disease -- meaning when an RSV becomes more severe and can cause pneumonia, bronchitis, shortness of breath and more.
- Investor's Business Daily
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
